Raymond James & Associates Lantern Pharma Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LTRN
# of Institutions
34Shares Held
1.31MCall Options Held
39.8KPut Options Held
6.1K-
Vanguard Group Inc Valley Forge, PA364KShares$1.24 Million0.0% of portfolio
-
Cm Management, LLC185KShares$632,7000.57% of portfolio
-
New Edge Advisors, LLC New Orleans, LA137KShares$469,6950.0% of portfolio
-
Geode Capital Management, LLC Boston, MA87.4KShares$299,0270.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny84KShares$287,2800.0% of portfolio
About Lantern Pharma Inc.
- Ticker LTRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,830,900
- Market Cap $37M
- Description
- Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...